2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
نویسندگان
چکیده
Open Access Oral presentation 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) N Ruperto*1, P Quartier2, N Wulffraat3, P Woo4, A Loy1, R Mouy2, B BaderMeunier2, B Prakken3, E Noseda5, C Rordorf5 and Martini for the Paediatric Rheumatology International Trials Organisation (PRINTO) A1
منابع مشابه
PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
Introduction Canakinumab (CAN), a selective, fully human, antiinterleukin-1b monoclonal antibody, has been shown to be efficacious in SJIA patients (pts) in 2 phase 3 trials: Trial 1 (4-wk, randomized placebo [PBO]-controlled) and Trial 2 (open-label CAN treatment [Part 1] followed by a randomized PBO-controlled withdrawal phase [Part 2]). In Trial 1, statistically significantly more CAN than P...
متن کاملEfficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
OBJECTIVES To describe the efficacy, safety, and exposure-response relationship of canakinumab in a subgroup of patients with systemic juvenile idiopathic arthritis (SJIA) aged ≥16 years, representative of adult-onset Still's disease (AOSD) patients, and to compare this subgroup with those of children and young adolescents with SJIA by pooling clinical data collected during the development prog...
متن کاملCanakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
Introduction Systemic juvenile idiopathic arthritis (SJIA), an interleukin-1b (IL-1b)-mediated autoinflammatory disease, is characterized by recurrent flares of active disease. Treatment with canakinumab (CAN), a selective, human, anti-IL-1b monoclonal antibody allows for successful steroid dose reduction/discontinuation and reduces risk to experience a flare in patients with SJIA [1]. CAN is a...
متن کاملEarly changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
BACKGROUND Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). METHODS Gene expression was measured in patients with febrile SJIA and in matche...
متن کاملUse of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
Introduction The composite score JADAS 2 27-CRP (J27), 10-CRP (J10), and cut-off values for inactive (ID), low (LDA), moderate (MDA) and high disease activity (HDA) were designed to monitor the level of disease activity in all JIA subtypes. The efficacy of canakinumab (CAN), a selective, human, anti-IL-1b monoclonal antibody, was previously demonstrated in SJIA in phase III trials using aACR-JI...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 6 شماره
صفحات -
تاریخ انتشار 2008